← Back to Search

DCFPyL PET/CT for Prostate Cancer

Phase 2

Recruiting

Research Sponsored by Hoag Memorial Hospital Presbyterian

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 4 weeks

Awards & highlights

Study Summary

This trial suggests that PyL, a novel PET tracer, may be more effective than the standard of care imaging for detecting prostate cancer metastases.

Eligible Conditions

Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 4 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 4 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Detection of unsuspected metastases in biochemically recurrent prostate cancer

Detection of unsuspected metastases in high risk prostate cancer

Trial Design

2Treatment groups

Experimental Treatment

Group I: High risk prostate cancerExperimental Treatment1 Intervention

DCFPyL PET/CT will be compared to CT/bone scan for detection of unsuspected metastases in patients with high risk prostate cancer and planned prostatectomy or or radiation therapy

Group II: Biochemically recurrent prostate cancerExperimental Treatment1 Intervention

DCFPyL PET/CT will be utilized for detection of unsuspected metastases in patients with biochemically recurrent prostate cancer, but with no evidence of disease on CT/bone scan.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Hoag Memorial Hospital PresbyterianLead Sponsor

34 Previous Clinical Trials

14,511 Total Patients Enrolled

1 Trials studying Prostate Cancer

100 Patients Enrolled for Prostate Cancer

Deborah Fridman, PsyD, RNStudy DirectorHoag Memorial Hospital Presbyterian

1 Previous Clinical Trials

60 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current regulatory status of DCFPyL PET/CT?

"Our team's evaluation of the safety profile of DCFPyL PET/CT was a 2, as this is still an early Phase 2 trial and there are only limited findings on its efficacy."

Answered by AI

How many people are currently participating in this experiment?

"Affirmative. Clinicaltrials.gov indicates that this medical trial is accepting applications, having first been posted on February 1st 2021 and last updated July 26th 2021. This particular study requires 184 participants from a single location to complete the testing protocol."

Answered by AI

Is the recruitment process for this study still ongoing?

"Correct. Data on clinicaltrials.gov verifies that this experiment, which was published on February 1st 2021, is actively enrolling participants. About 184 patients are sought to be recruited from one particular medical facility."

Answered by AI

Recent research and studies

RadiologyJournal

<sup>18</sup>f-dcfpyl PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer: Prospective Trial with Pathologic Confirmation

Ulaner, Gary A., Beth Thomsen, Jeffrey Bassett, Robert Torrey, Craig Cox, Kevin Lin, Trushar Patel, et al.. 2022. “18f-dcfpyl PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer: Prospective Trial with Pathologic Confirmation”. Radiology. Radiological Society of North America (RSNA). doi:10.1148/radiol.220218.

clinicaltrials.govStudy

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

Gary Ulaner 2021. "PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04700332.

All > Recurrent Prostate Cancer